Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! The rivalry between Eli Lilly and Novo Nordisk extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s. The two drugmakers are also competing to develop once-weekly insulin injections. Those shots could provide a longer-lasting and more convenient option than daily insulin and other common treatments for managing diabetes. Patients with Type 1 diabetes require insulin ever ...